Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of a groundbreaking treatment for geographic atrophy (GA), an advanced form of dry age-related macular …
Ocugen Advances in Revolutionary Gene Therapy for Age-Related Macular Degeneration Read More
MALVERN, PA — In a significant advancement for retinitis pigmentosa (RP) treatment, Ocugen, Inc. (NASDAQ: OCGN) has received favorable scientific advice from the European Medicines Agency (EMA) regarding its pivotal …
Ocugen’s Gene Therapy OCU400 Moves Closer to European Market with EMA’s Positive Opinion Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced a significant milestone in its Phase 1/2 …
Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial Read More MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN released its general business update on Tuesday, revealing promising strides in the pursuit of transformative treatments for blindness diseases. The Pennsylvania-based company’s dedication …
Ocugen Inc. Embarks on A Game-Changing Era With Revolutionary Gene Therapy Initiatives Read More MALVERN, PA — In a promising development for the treatment of Stargardt disease, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company based in Chester County, Pennsylvania, has announced the completion of …
Ocugen Achieves Clinical Milestone in Stargardt Disease Treatment Read More MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced the commencement of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA), a gene therapy candidate being developed to …
Ocugen Initiates Phase 1/2 GARDian Clinical Trial for Stargardt Disease Therapy Read More